Reduction of uranium transfer by local chelation in simulated wounds in rats.
The aim of the paper is to develop a new approach to treat uranium-contaminated wounds. The efficacy of a local uranium chelator, carballylic amido bis phosphonic acid (CAPBP) was assessed using two different uranium compounds. Rats were contaminated by intramuscular injections of uranyl nitrate or an industrial U04 compound to simulate wound contamination. CAPBP was injected intramuscularly (i.m.) or intraperitoneally (i.p.) at a dosage of 30 micromol kg(-1). In one experiment, the local administration of CAPBP was combined with a systemic administration of ethane-1-hydroxy-1,1-biphosphonate (EHBP). The local CAPBP treatment resulted in increased retention of uranium at the wound site: about 30% for uranyl nitrate or U04 after the first day and about 15% of UO4 after the third day. Consequently, it reduced uranium translocation into the blood and deposition in the kidneys and bone. The combined treatment reduced the uranium deposits in the kidneys, bone and carcass to about one-half of those observed in controls 3 days after U04 contamination. The local CAPBP treatment increased the interval of time between contamination and uranium deposit in the target organs. Thus, it can increase the efficacy of nonspecific local treatments or specific systemic treatments. It could be given rapidly through spray or gel after an accident.
Houpert
P
P
Institut de Protection et de Sûreté Nucléaire, Département de Protection de la santé de l'Homme et de Dosimétrie, Fontenay aux Roses, France.
Chazel
V
V
Paquet
F
F
Bailly
T
T
Burgada
R
R
Henge-Napoli
M H
MH
D000818:Animals; D001842:Bone and Bones / Q000737:chemistry; D002614:Chelating Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D007273:Injections, Intramuscular; D007668:Kidney / Q000737:chemistry; D008297:Male; D063065:Organophosphonates / Q000494:pharmacology*; D011832:Radiation Injuries; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D014501:Uranium / Q000378:metabolism* / Q000493:pharmacokinetics*; D017974:Uranium Compounds / Q000493:pharmacokinetics; D014947:Wounds and Injuries
D002614:Chelating Agents; D063065:Organophosphonates; D017974:Uranium Compounds; D014501:Uranium